177 related articles for article (PubMed ID: 29170254)
41. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
Rosenfeld C; Cheever MA; Gaiger A
Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
43. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
44. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.
Kunz JB; Rausch T; Bandapalli OR; Eilers J; Pechanska P; Schuessele S; Assenov Y; Stütz AM; Kirschner-Schwabe R; Hof J; Eckert C; von Stackelberg A; Schrappe M; Stanulla M; Koehler R; Avigad S; Elitzur S; Handgretinger R; Benes V; Weischenfeldt J; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2015 Nov; 100(11):1442-50. PubMed ID: 26294725
[TBL] [Abstract][Full Text] [Related]
45. Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells.
Ullmark T; Montano G; Järvstråt L; Jernmark Nilsson H; Håkansson E; Drott K; Nilsson B; Vidovic K; Gullberg U
Biochem Biophys Res Commun; 2017 Jan; 482(4):802-807. PubMed ID: 27889611
[TBL] [Abstract][Full Text] [Related]
46. A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia.
Paganin M; Buldini B; Germano G; Seganfreddo E; Meglio Ad; Magrin E; Grillo F; Pigazzi M; Rizzari C; Cazzaniga G; Khiabanian H; Palomero T; Rabadan R; Ferrando AA; Basso G
Pediatr Blood Cancer; 2016 Sep; 63(9):1660-3. PubMed ID: 27149388
[TBL] [Abstract][Full Text] [Related]
47. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
Tedeschi PM; Kathari YK; Johnson-Farley N; Bertino JR
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1247-52. PubMed ID: 25917288
[TBL] [Abstract][Full Text] [Related]
48. Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.
Poglio S; Lewandowski D; Calvo J; Caye A; Gros A; Laharanne E; Leblanc T; Landman-Parker J; Baruchel A; Soulier J; Ballerini P; Clappier E; Pflumio F
Oncotarget; 2016 Jul; 7(27):41599-41611. PubMed ID: 27191650
[TBL] [Abstract][Full Text] [Related]
49. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis.
Svensson E; Eriksson H; Gekas C; Olofsson T; Richter J; Gullberg U
Exp Cell Res; 2005 Aug; 308(1):211-21. PubMed ID: 15907324
[TBL] [Abstract][Full Text] [Related]
50. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
51. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome.
Busse A; Gökbuget N; Siehl JM; Hoelzer D; Schwartz S; Rietz A; Thiel E; Keilholz U
Ann Hematol; 2009 Dec; 88(12):1199-205. PubMed ID: 19404640
[TBL] [Abstract][Full Text] [Related]
52. Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts in Egyptian acute lymphoblastic leukemia patients.
Sadek HA; El-Metnawey WH; Shaheen IA; Korshied MM; Mohamed AS
J Investig Med; 2011 Dec; 59(8):1258-62. PubMed ID: 21804407
[TBL] [Abstract][Full Text] [Related]
53. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status.
Ohnishi K; Scuric Z; Schiestl RH; Okamoto N; Takahashi A; Ohnishi T
Radiat Res; 2006 Sep; 166(3):454-62. PubMed ID: 16972754
[TBL] [Abstract][Full Text] [Related]
54. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.
Bond J; Graux C; Lhermitte L; Lara D; Cluzeau T; Leguay T; Cieslak A; Trinquand A; Pastoret C; Belhocine M; Spicuglia S; Lheritier V; Leprêtre S; Thomas X; Huguet F; Ifrah N; Dombret H; Macintyre E; Boissel N; Asnafi V
J Clin Oncol; 2017 Aug; 35(23):2683-2691. PubMed ID: 28605290
[TBL] [Abstract][Full Text] [Related]
55. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
56. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
57. Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells.
Gonzalez-Sanchez L; Cobos-Fernandez MA; Lopez-Nieva P; Villa-Morales M; Stamatakis K; Cuezva JM; Marin-Rubio JL; Vazquez-Dominguez I; Gonzalez-Vasconcellos I; Salido E; Llamas P; Lopez-Lorenzo JL; Santos J; Fernandez-Piqueras J
Carcinogenesis; 2020 Aug; 41(8):1113-1122. PubMed ID: 31734690
[TBL] [Abstract][Full Text] [Related]
58. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
[TBL] [Abstract][Full Text] [Related]
59. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
60. A tumor suppressor and oncogene: the WT1 story.
Yang L; Han Y; Suarez Saiz F; Minden MD
Leukemia; 2007 May; 21(5):868-76. PubMed ID: 17361230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
